Modifying Disease Progression Through
Cell Repair and Restoration
AVIPERO was founded by core scientific expertise with a keen interest in therapeutic disruptors in clinical indications where treatments stagnated due to misunderstood pathologies. Our target was cellular and tissue repair.
In irreversible injury and senescence models, AVIPERO identified beta1 integrin as a novel target for inducing repair and regeneration and reversing aging. AVIPERO's unique platform employs novel function-modifying (allosteric) antibodies, which normalizes its functions. In addition, AVIPERO has identified a unique domain within beta1 integrin (Hybrid domains), stabilizing the receptor's conformation into its normal low-affinity physiological state.
Antibodies against beta1-integrin inhibited tumour growth in mouse models of breast cancer, prostate cancer, osteosarcoma and melanoma. Anti-beta1 integrin antibody inhibits metastasis of breast cancer and more specifically triple negative breast cancer (TNBC).